VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PACB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PACBPacific Biosciences of California, Inc.
$1.73$537M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPACBBalance Sheet

Pacific Biosciences of California, Inc. (PACB) Balance Sheet

18Y historyFree accessUpdated daily

The company's financial position appears increasingly fragile, with the debt-to-equity ratio surging to 297.29 and total equity collapsing to $2.4 million by 2026Q1.

PACB Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Total Current Assets369.52M375.03M495.68M742.05M852.07M1.1B355.59M81.05M131.66M101.62M109.01M110.54M117.76M126.46M115M199.6M293.11M93.75M106.93M
Cash & Short-Term Investments275.98M279.51M389.93M631.42M772.32M1.04B318.81M49.1M102.35M62.87M71.98M82.27M101.35M112.53M100.58M177.43M283.67M92.73M106.05M
Cash Only56.29M63.71M55.37M179.91M325.09M460.73M81.61M29.63M18.84M62.87M16.77M82.27M36.45M26.36M46.54M58.87M147.65M89.23M78.46M
Short-Term Investments219.69M215.8M334.56M451.5M447.23M583.67M237.2M19.47M83.51M055.21M064.9M86.17M54.04M118.57M136.02M3.5M27.59M
Accounts Receivable29.35M35.45M27.52M36.62M18.79M24.24M16.84M15.27M8.6M13.43M16.42M15.24M3.41M2.75M2.82M4.56M341K00
Days Sales Outstanding72.880.8665.2366.6553.4467.7977.961.3139.952.4666.0759.9720.5235.5739.6449.1274.35--
Inventory51.02M49.28M58.76M56.68M50.38M24.6M14.23M13.31M17.88M23.07M15.63M10.96M11.34M10.05M9.59M15.52M6.86M00
Days Inventory Outstanding187.87164.54183.72140.02231.98125.31112.1186.28121.9143.15122.58101.66111.24168.56139.8271.91---
Other Current Assets13.16M10.79M19.47M17.34M300K500K836K300K00476K741K107K02.01M0000
Total Non-Current Assets412.85M409.05M764.77M1B915.01M905.84M58.39M66.94M38.62M42.47M28.87M20.57M6.76M9.73M14.68M18.71M12.63M7.35M6.18M
Property, Plant & Equipment65.22M65.84M46.6M69.03M81.34M79.12M54.85M62.9M34.07M37.92M14.56M8.55M6.6M9.24M14.33M18.4M12.31M7.14M6.03M
Fixed Asset Turnover2.44x2.43x3.31x2.91x1.58x1.65x1.44x1.45x2.31x2.46x6.23x10.85x9.18x3.05x1.81x1.84x0.14x0.02x0.15x
Goodwill317.76M317.76M317.76M462.26M409.97M409.97M0000000000000
Intangible Assets14.1M15.12M389.57M456.98M410.25M410.98M0000000000000
Long-Term Investments3.1M1.53M0000004.5M4.5M4.5M9.5M0000000
Other Non-Current Assets14.19M8.79M10.84M15.7M13.45M5.76M3.54M4.04M43K45K9.81M2.52M162K490K354K317K322K211K154K
Total Assets782.37M784.08M1.26B1.75B1.77B2.01B413.98M147.99M170.28M144.08M137.88M131.11M124.52M136.19M129.68M218.32M305.75M101.1M113.11M
Asset Turnover0.20x0.20x0.12x0.11x0.07x0.07x0.19x0.61x0.46x0.65x0.66x0.71x0.49x0.21x0.20x0.16x0.01x0.00x0.01x
Asset Growth %-136.83%-37.79%-27.81%-1.19%-11.95%384.8%179.74%-13.09%18.18%4.5%5.17%5.29%-8.56%5.01%-40.6%-28.6%202.43%-10.62%-
Total Current Liabilities65.36M54.42M66.3M95.03M263.33M71.71M38.5M49.15M20.35M22.32M33.77M21.93M31.49M22.55M14.74M19.38M20.84M8.42M4.7M
Accounts Payable13.61M20.77M16.59M15.06M12.03M11M3.58M8.37M6.74M9.09M8.36M4.75M5.61M1.72M2.99M4.74M9.52M5.78M1.84M
Days Payables Outstanding59.6369.3451.8737.2155.3856.0428.254.2445.9356.4465.5444.0755.0428.843.5583.1---
Short-Term Debt277K448K0490K1.84M1.61M015.87M00000000110K01.3M
Deferred Revenue (Current)31.19M013.86M16.34M30.5M10.98M8.72M7.61M6.54M6.32M7.13M17.64M12.91M10.83M3.38M6.58M3.22M01.1M
Other Current Liabilities35.14M32.75M3.22M7.84M175.5M4.15M4.52M225K5.09M5.65M9.72M7.66M6.65M4.65M3.54M844K463K00
Current Ratio5.65x6.89x7.48x7.81x3.24x15.36x9.24x1.65x6.47x4.55x3.23x5.04x3.74x5.61x7.80x10.30x14.06x11.13x22.74x
Quick Ratio4.87x5.99x6.59x7.21x3.04x15.01x8.87x1.38x5.59x3.52x2.76x4.54x3.38x5.16x7.15x9.50x13.74x11.13x22.74x
Cash Conversion Cycle201.04176.06197.07169.46230.04137.06161.8193.35115.87139.17123.11117.5676.72175.33135.9237.94---
Total Non-Current Liabilities714.64M724.32M687.55M949.68M940.85M1.14B39.99M43.91M35.87M35.66M19.44M35.64M38.09M44.45M5.56M7.48M5.04M269.8M201.79M
Long-Term Debt644.11M702.42M647.49M892.24M896.68M896.07M0014.66M13.63M16.11M14.95M14.12M13.35M002.93M00
Capital Lease Obligations222.43M57.04M14.91M31.61M41.07M49.97M37.67M41.96M000002.4M2.61M2.79M2.93M00
Deferred Tax Liabilities00000-25.05M0000356K-786K944K-2.4M00000
Other Non-Current Liabilities7.98M-55.01M19.25M20.3M1.3M198.24M752K013.78M14.64M2.04M4.44M3.1M1.66M2.15M3.08M-813K269.8M201.79M
Total Liabilities780M778.73M753.85M1.04B1.2B1.22B78.49M93.07M56.21M57.98M53.22M57.57M69.57M67M20.3M26.85M25.88M278.22M206.5M
Total Debt703.39M759.46M672.43M933.93M948.48M955.36M42M61.67M14.66M13.63M16.11M14.95M14.12M15.96M2.79M2.93M3.04M01.3M
Net Debt647.1M695.75M617.06M754.02M623.39M494.63M-39.61M32.05M-4.18M-49.24M-659K-67.32M-22.32M-10.4M-43.75M-55.94M-144.61M-89.23M-77.16M
Debt / Equity297.29x141.98x1.33x1.33x1.68x1.21x0.13x1.12x0.13x0.16x0.19x0.20x0.26x0.23x0.03x0.02x0.01x--
Debt / EBITDA-4.66x------------------
Net Debt / EBITDA-4.28x------------------
Interest Coverage-44.67x-77.52x-22.08x-21.18x-20.39x-20.94x111.12x-31.22x-41.33x-30.56x-22.00x-9.83x-22.39x-31.00x-343.76x-380.14x---
Total Equity2.37M5.35M506.59M701.3M562.9M790.99M335.49M54.92M114.06M86.1M84.67M73.54M54.95M69.18M109.38M191.46M279.87M-177.12M-93.39M
Equity Growth %-375.92%-98.94%-27.76%24.59%-28.84%135.77%510.91%-51.85%32.47%1.69%15.13%33.83%-20.57%-36.75%-42.87%-31.59%258.01%-89.66%-
Book Value per Share0.010.021.762.772.513.871.920.360.840.810.950.970.781.101.963.5510.41-228.89-120.68
Total Shareholders' Equity2.37M5.35M506.59M701.3M562.9M790.99M335.49M54.92M114.06M86.1M84.67M73.54M54.95M69.18M109.38M191.46M279.87M-177.12M-93.39M
Common Stock311K302K294K268K227K221K192K153K150K116K93K80K74K684.48M645.37M55K53K00
Retained Earnings-2.7B-2.7B-2.15B-1.84B-1.53B-1.22B-1.04B-1.07B-982.11M-879.73M-787.54M-713.17M-681.47M-615.31M-536.02M-441.56M-332.17M-192M-104.3M
Treasury Stock0000000000000000000
Accumulated OCI-147K457K422K219K-4.76M-1.09M85K5K-36K-32K5K-7K9K14K30K57K-21K1K44K
Minority Interest0000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Solvency and liquidity constraints

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Rapid Erosion of Equity Base

As reported in recent financial filings, PACB's equity has plummeted from $701.3 million in 2023Q4 to a mere $2.4 million by 2026Q1, signaling a severe deterioration in the company's net worth driven by persistent operational losses and the accumulation of significant debt obligations.

The precipitous decline in equity suggests that the company is rapidly consuming its capital base to fund ongoing R&D and commercialization efforts. This trajectory indicates that the business model is currently unable to generate sufficient internal value to offset its operational burn, leaving the balance sheet increasingly reliant on external financing.

Leverage Ratios Reflect Financial Distress

Based on the latest quarterly data, PACB's debt-to-equity ratio has surged to an alarming 297.29, a dramatic increase from 1.33 in 2023Q4, which highlights the company's heavy reliance on debt financing amidst a shrinking equity cushion and limited operational cash flow generation.

The massive spike in leverage suggests that the company's capital structure has become highly sensitive to interest rate fluctuations and credit market conditions. Investors should monitor whether this debt load imposes restrictive covenants that could further limit the company's strategic flexibility during its critical product transition phase.

Cash Reserves Under Severe Pressure

According to the most recent balance sheet, cash reserves have dwindled to $56.3 million as of 2026Q1, down significantly from the $180.2 million reported in 2023Q4, indicating a narrowing runway to support the company's high-burn operating model without further dilutive capital raises.

While the current ratio remains elevated, the absolute level of cash relative to the company's historical burn rate suggests a precarious liquidity position. This trend implies that the company may face imminent pressure to secure additional funding, which could lead to significant shareholder dilution or unfavorable debt refinancing terms.

Goodwill Impairment Risk Remains Elevated

As evidenced by the company's reported figures, goodwill remains a substantial component of total assets at $317.8 million, which warrants further investigation given the persistent operating losses and the potential for future impairment charges if the Revio platform fails to meet long-term commercial expectations.

The presence of significant goodwill on a balance sheet with near-zero equity suggests that the company's asset valuation is highly sensitive to management's future growth assumptions. Any downward revision in these assumptions could trigger impairment charges, further eroding the already fragile equity position and potentially violating debt covenants.

PACB — Frequently Asked Questions

Quick answers to the most common questions about buying PACB stock.

What are the total assets of Pacific Biosciences of California, Inc. (PACB)?

As of 2025, Pacific Biosciences of California, Inc. (PACB) had total assets of $784.1M including $375.0M in current assets.

How much debt does Pacific Biosciences of California, Inc. (PACB) have?

Pacific Biosciences of California, Inc. (PACB) carries total debt of $759.5M, offset by $279.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Pacific Biosciences of California, Inc.?

Pacific Biosciences of California, Inc. (PACB) has total shareholders' equity (book value) of $5.3M ($0.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Pacific Biosciences of California, Inc.'s current ratio and liquidity?

Pacific Biosciences of California, Inc. (PACB) reported a current ratio of 6.89x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.